Phaseline

Companies › DualityBio

DualityBio: clinical trials, targets and expected readouts

10 active drug programs in 14 registered trials: 9 Phase 1, 3 Phase 2, 2 Phase 3; Oncology, Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DB-1303/BNT323
HER2-targeting bispecific antibody
ERBB2Phase 3HER2-positive Breast Cancer; Metastatic Breast Cancer; HER2-positive Advanced Solid TumorAug 2027
BNT327
Personalized neoantigen vaccine
–Phase 2Solid Tumors; Advanced Solid TumorAug 2027
DB-1305
OX40 agonist
–Phase 2Solid Tumors; Advanced Solid TumorAug 2027
DB-1311–Phase 2Solid TumorsJun 2030
DB-1419–Phase 1Solid Tumor, AdultFeb 2027
DB-2304–Phase 1Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus ErythematosusJun 2027
DB-1311/BNT324–Phase 1Advanced Solid TumorsDec 2027
DB-1310–Phase 1Advanced Solid TumorDec 2027
DB-1317–Phase 1Advanced/Metastatic Solid TumorsJun 2028
DB-1324–Phase 1Gastrointestinal CancerDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06554795DB-1419Phase 1Solid Tumor, AdultOncologyFeb 2027
NCT06625671DB-2304Phase 1Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus ErythematosusImmunologyJun 2027
NCT05438329BNT327Phase 1Advanced Solid TumorOncologyAug 2027
NCT05438329DB-1305Phase 1Advanced Solid TumorOncologyAug 2027
NCT05150691DB-1303/BNT323Phase 1HER2-positive Advanced Solid TumorOncologyAug 2027
NCT06265428DB-1303/BNT323Phase 3HER2-positive Breast CancerOncologyDec 2027
NCT05914116DB-1311/BNT324Phase 1Advanced Solid TumorsOncologyDec 2027
NCT05785741DB-1310Phase 1Advanced Solid TumorOncologyDec 2027
NCT07141706DB-1317Phase 1Advanced/Metastatic Solid TumorsOncologyJun 2028
NCT06018337DB-1303/BNT323Phase 3Metastatic Breast CancerOncologyAug 2028
NCT07263594DB-1324Phase 1Gastrointestinal CancerOncologyDec 2028
NCT06953089DB-1311Phase 2Solid TumorsOncologyJun 2030
NCT06953089BNT327Phase 2Solid TumorsOncologyJun 2030
NCT06953089DB-1305Phase 2Solid TumorsOncologyJun 2030

Targets

ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Companies built like this

SystImmune Aston Sci. Chengdu SciMount Pharmatech Shanghai Miracogen BioRay Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.